Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer : Episode 8
Opinion
Video
Clinical Management Considerations: Pneumonitis associated with T-DXd
Author(s):
Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.
EP: 1.Overview of Current ADCs in Breast Cancer
EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components
EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia
EP: 5.Navigating SG-related Diarrhea
EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
Now Viewing
EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd
EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP: 11.Future Perspectives on ADCs in Breast Cancer
EP: 12.Expert Insights: Investigational ADCs Safety Profiles
EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs
Video content above is prompted by the following:
- How often do you see pneumonitis in your clinical practice with trastuzumab deruxtecan (T-DXd)? Are there any potential patient risk factors for community oncologists to be aware of?
Related Videos
Related Content
